Forum Discussions

Forum Discussions

These novel Fora, in WEF-style format, will bring together corporate participants, neuroscientists and clinicians with outstanding experience in “hottest” research topics in the field of neurodegeneration to discuss the impact of newest preclinical results and cutting edge clinical findings on understanding and treatment development of neurodegenerative disorders. The objective is to exchange novel insights, challenges and solutions on the joint path forward to defining the future of Alzheimer’s and Parkinson’s therapeutics.

Each forum will be a moderated discussion with maximum 3 minutes introduction statement from each participant followed by questions from the audience. The forum is also open for journalists from different media, including lay press in and may report on progress made by the leaders in this field.

Forum Title



Blood-Based Biomarkers Comparison To CSF and Imaging Biomarkers. Assessment for Diagnoses & Treatment Effects; How to measure minimal clinical efficacy

Melissa Murray (USA)
Oskar Hansson (Sweden)

Wednesday, March 29, 2023

Immunotherapies In AD: From Basics To Approval

Susanne Hendrix (USA)
Alfred Sandrock (USA)

Wednesday, March 29, 2023

Phase I-III In AD:  Drug Development And Relevance For Heterogeneity Of The Disease

Angela Genge (Canada)
Jeffrey Cummings (USA)

Thursday, March 30, 2023

New Insights In The Development Of Biomarkers, Imaging And Therapy Of Alpha-Synuclein, LRKK2 & GBA Pathologies

Jamie Eberling (USA)
Walter Koroshetz (USA)

Thursday, March 30, 2023

Anti-Tau Therapies In Clinical Trials

Virginia Lee (USA)
Eckhard Mandelkow (Germany)

Friday, March 31, 2023

Drug Development & Biomarkers In Rare CNS Diseases (ALS, FTD): From Basics Towards Approval

Laura Ranum (USA)
Henrik Zetterberg (Sweden)

Saturday, April 1 2023